Ranbaxy launches Remicade biosimilar

Our Bureau New Delhi | Updated on December 01, 2014 Published on December 01, 2014

Ranbaxy Laboratories, on Monday, announced the launch of Infimab, the first Remicade (Infliximab) biosimilar in India.

The drug is used in treatment of inflammatory diseases, including rheumatoid arthritis, Crohn’s Disease, ankylosing spondylitis, ulcerative colitis, psoriatic arthritis and also psoriasis.

A company statement said, “Infimab is being introduced in the Indian market through a licensing partnership with Epirus Biopharmaceuticals, a US and Swiss-based biopharmaceutical company focused on the global development and commercialisation of biosimilar monoclonal antibodies.”

In a statement, Rajeev Sibal, Vice-President and Country Head-India Region, Ranbaxy, said that the drug will be available in India at a price point that is significantly discounted compared to the innovator drug Remicade.

Published on December 01, 2014
This article is closed for comments.
Please Email the Editor